ATE533503T1 - Präventive melanomimpfung - Google Patents
Präventive melanomimpfungInfo
- Publication number
- ATE533503T1 ATE533503T1 AT05731001T AT05731001T ATE533503T1 AT E533503 T1 ATE533503 T1 AT E533503T1 AT 05731001 T AT05731001 T AT 05731001T AT 05731001 T AT05731001 T AT 05731001T AT E533503 T1 ATE533503 T1 AT E533503T1
- Authority
- AT
- Austria
- Prior art keywords
- melanoma
- vaccination
- malignancy
- risk
- relates
- Prior art date
Links
- 238000002255 vaccination Methods 0.000 title abstract 6
- 201000001441 melanoma Diseases 0.000 title abstract 5
- 230000003449 preventive effect Effects 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 4
- 230000036210 malignancy Effects 0.000 abstract 3
- 201000011510 cancer Diseases 0.000 abstract 2
- 230000000069 prophylactic effect Effects 0.000 abstract 2
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 206010025323 Lymphomas Diseases 0.000 abstract 1
- 206010039491 Sarcoma Diseases 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 210000000481 breast Anatomy 0.000 abstract 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 230000000385 effect on melanoma Effects 0.000 abstract 1
- 210000003238 esophagus Anatomy 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 210000003734 kidney Anatomy 0.000 abstract 1
- 231100000518 lethal Toxicity 0.000 abstract 1
- 230000001665 lethal effect Effects 0.000 abstract 1
- 244000005700 microbiome Species 0.000 abstract 1
- 230000001681 protective effect Effects 0.000 abstract 1
- 229940126577 synthetic vaccine Drugs 0.000 abstract 1
- 210000003932 urinary bladder Anatomy 0.000 abstract 1
- 229960001515 yellow fever vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04009135A EP1586330A1 (de) | 2004-04-16 | 2004-04-16 | Impfstoffe gegen Melanoma |
| PCT/EP2005/004050 WO2005099750A1 (en) | 2004-04-16 | 2005-04-15 | Vaccination against malignant melanoma using bcg and/or vaccinia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE533503T1 true ATE533503T1 (de) | 2011-12-15 |
Family
ID=34924641
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05731001T ATE533503T1 (de) | 2004-04-16 | 2005-04-15 | Präventive melanomimpfung |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20110229503A1 (de) |
| EP (2) | EP1586330A1 (de) |
| AT (1) | ATE533503T1 (de) |
| AU (1) | AU2005232396B2 (de) |
| CA (1) | CA2564115A1 (de) |
| WO (1) | WO2005099750A1 (de) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL212047B1 (pl) * | 2000-11-23 | 2012-08-31 | Bavarian Nordic As | Zmodyfikowany wirus krowianki szczepu Ankara MVA-BN i jego pochodna, genom i zawierające je kompozycja farmaceutyczna, zwłaszcza szczepionka oraz ich zastosowania |
| US8501198B2 (en) | 2004-06-07 | 2013-08-06 | Qu Biologics Inc. | Tissue targeted antigenic activation of the immune response to treat cancers |
| US9107864B2 (en) | 2004-06-07 | 2015-08-18 | Qu Biologics Inc. | Tissue targeted antigenic activation of the immune response to treat cancers |
| US8034359B2 (en) | 2004-06-07 | 2011-10-11 | Qu Biologics Inc. | Tissue targeted antigenic activation of the immune response to cancers |
| US8980279B2 (en) | 2010-07-26 | 2015-03-17 | Qu Biologics | Personalized site-specific immunomodulation |
| NZ702796A (en) | 2010-07-26 | 2017-03-31 | Qu Biologics Inc | Immunogenic anti-inflammatory compositions |
| CN103497927B (zh) * | 2013-10-21 | 2016-02-10 | 深圳大学 | 表达分泌金葡菌肠毒素蛋白的重组bcg活菌菌株、活菌疫苗及其构建方法和应用 |
| EP3116541B1 (de) | 2014-03-12 | 2019-11-27 | Bavarian Nordic A/S | Verwendung von öl-und-wasser-emulsionen zur steigerung der humoralen immunantwort |
| JP6632607B2 (ja) | 2014-05-02 | 2020-01-22 | クー バイオロジックス インク．Ｑｕ Ｂｉｏｌｏｇｉｃｓ Ｉｎｃ． | 抗微生物免疫修飾 |
| CN106063932B (zh) * | 2015-04-20 | 2021-07-13 | 上海市公共卫生临床中心 | 使用仙台病毒作为载体的抗结核杆菌疫苗 |
| US11160854B2 (en) | 2016-07-11 | 2021-11-02 | Limited Liability Company “Cancernet” | Immunostimulatory preparation exhibiting antitumor activity |
| CN109528775A (zh) * | 2017-09-22 | 2019-03-29 | 中山大学 | 脆弱拟杆菌在制备用于治疗和预防肿瘤的药物中的应用 |
| BR112021006941A2 (pt) | 2018-10-19 | 2021-08-31 | The Francis Crick Institute Limited | Antígenos de câncer inovadores e métodos |
| SG11202112328TA (en) * | 2019-05-15 | 2021-12-30 | Codagenix Inc | Attenuated yellow fever virus and uses thereof for the treatment of cancer |
| AU2020302285A1 (en) | 2019-06-28 | 2021-12-02 | Enara Bio Limited | Novel cancer antigens and methods |
| WO2021005338A2 (en) | 2019-07-05 | 2021-01-14 | The Francis Crick Institute Limited | Novel cancer antigens and methods |
| JP7834016B2 (ja) | 2019-07-05 | 2026-03-23 | ザ フランシス クリック インスティチュート リミティッド | 新規な癌抗原及び方法 |
| CN116057067A (zh) * | 2020-04-17 | 2023-05-02 | 弗朗西斯·克里克研究所有限公司 | 用于治疗黑素瘤的ctl抗原的融合蛋白 |
| JP2023522193A (ja) | 2020-04-17 | 2023-05-29 | ザ フランシス クリック インスティチュート リミティッド | 抗原プール |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4952496A (en) * | 1984-03-30 | 1990-08-28 | Associated Universities, Inc. | Cloning and expression of the gene for bacteriophage T7 RNA polymerase |
-
2004
- 2004-04-16 EP EP04009135A patent/EP1586330A1/de not_active Withdrawn
-
2005
- 2005-04-15 AT AT05731001T patent/ATE533503T1/de active
- 2005-04-15 CA CA002564115A patent/CA2564115A1/en not_active Abandoned
- 2005-04-15 AU AU2005232396A patent/AU2005232396B2/en not_active Ceased
- 2005-04-15 EP EP05731001A patent/EP1740205B1/de not_active Expired - Lifetime
- 2005-04-15 US US11/578,544 patent/US20110229503A1/en not_active Abandoned
- 2005-04-15 WO PCT/EP2005/004050 patent/WO2005099750A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005099750A1 (en) | 2005-10-27 |
| US20110229503A1 (en) | 2011-09-22 |
| EP1740205B1 (de) | 2011-11-16 |
| AU2005232396A1 (en) | 2005-10-27 |
| EP1586330A1 (de) | 2005-10-19 |
| CA2564115A1 (en) | 2005-10-27 |
| AU2005232396B2 (en) | 2011-05-26 |
| EP1740205A1 (de) | 2007-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE533503T1 (de) | Präventive melanomimpfung | |
| CR9443A (es) | Vacuna de toxoide de c. perfringens alfa | |
| BRPI0520330B8 (pt) | adjuvante a base de ácido polinosínico-policitidílico | |
| MX395525B (es) | Composiciones inmunogenicas para usar en vacunas neumococicas. | |
| MX375202B (es) | Composiciones adyuvantes novedosas. | |
| ATE451119T1 (de) | Untereinheit-impfstoff gegen das respiratorische synzytialvirus | |
| MX392525B (es) | Composiciones inmunogenicas para su uso en vacunas neumococicas | |
| NO20015073L (no) | Vaksiner | |
| ATE426412T1 (de) | Adjuvante influenza-vakzine | |
| HK1212249A1 (en) | Bioconjugates comprising modified antigens and uses thereof | |
| PL2433954T3 (pl) | Identyfikacja związanych z nowotworem antygenów w celu diagnozowania i leczenia | |
| BRPI0510570A (pt) | composição de vacina | |
| ATE458496T1 (de) | Hiv-vakzine und anwendungsverfahren | |
| ATE269104T1 (de) | Salmonella impfstoff, der keinen antikörper gegen flagellin oder gegen flagella induziert | |
| WO2005026192A3 (en) | Hpv cd8+ t-cell epitopes | |
| WO2011112906A3 (en) | Novel immunogens and methods for discovery and screening thereof | |
| PL404247A1 (pl) | Koniugat oligocukru LOS Bordetella pertussis i toksyny krztuśca i jego zastosowanie w profilaktyce i leczeniu zakażeń wywoływanych przez Bordetella pertussis | |
| AR045416A1 (es) | Coadyuvante de linfocitos humanos para vacunas | |
| UY31510A1 (es) | Vacunacontra la malaria, especifica para el parasito plasmodium falciparum | |
| PT1305041E (pt) | Medicamento para a imunoterapia de tumores malignos | |
| ATE359815T1 (de) | Streptococcus-phocae-vakzine | |
| ATE424844T1 (de) | Kombinationsvakzine für geflügel | |
| DE602005021873D1 (de) | Neues impfstoffadjuvans und dessen herstellung und verwendung | |
| ATE419003T1 (de) | Mycobakterielle proteinantigene für krebstherapie und impfung | |
| NO20072099L (no) | Anvendelse av epotiloner ved behandling av benmetastaser og bentumorer eller kreft |